- Trial phase
- Phase 2
- Time to market
- If Phase 3 begins in 2027, a typical 12-18 month enrollment and follow-up period would put Phase 3 readout around 2028-2029, with potential FDA filing around 2029-2030 at the earliest, assuming positive results.
- Why 4/10
- Emvistegrast is a Phase 2 drug whose next hard catalyst (Phase 3 topline readout) is likely more than 12 months away, and it represents a small part of Gilead's large, diversified pipeline (HIV, oncology, liver disease). The Phase 2 data was already released on October 19, 2026, so no upcoming binary event is scheduled within the next ~12 months.
The Phase 2 data is now public (October 19, 2026). The next catalyst is the planned Phase 3 monotherapy study initiation in 2027, which is not a hard binary event. Investors should watch for the Phase 3 trial design details, enrollment timelines, and any expansion into Crohn's disease or combination regimens. The key competitive watchpoints are Eli Lilly's oral alpha4/beta7 inhibitor zotemtegrast (Phase 2) and Takeda's Entyvio franchise facing biosimilar erosion.
Price Chart
Executive Summary
Emvistegrast (GS-1427) is Gilead Sciences' investigational once-daily oral pill for moderate to severe ulcerative colitis. It works by blocking the alpha4/beta7 integrin pathway, the same clinically validated target as Takeda's blockbuster injectable Entyvio (vedolizumab), but in an oral format. On October 19, 2026, Gilead reported positive Phase 2 SWIFT trial results: the 200mg dose achieved 66% clinical response and 31% clinical remission at 12 weeks versus 37% and 8% for placebo, respectively. The drug was generally well tolerated. Gilead plans to start a Phase 3 monotherapy study in 2027. For a large-cap diversified biotech like Gilead, emvistegrast is an important pipeline asset but not a near-term binary catalyst.
How It Works
Emvistegrast is an oral small-molecule pill that blocks the alpha4/beta7 integrin, a protein on the surface of certain immune cells that acts like a homing beacon directing those cells to the gut. By blocking this beacon, the drug prevents inflammatory immune cells from entering intestinal tissue, reducing the chronic inflammation that causes ulcerative colitis symptoms. This is the same mechanism as the injected drug Entyvio (vedolizumab), but delivered as a convenient once-daily pill.
Trial Status
The Phase 2 SWIFT dose-ranging study (NCT06290934) enrolled 238 adults with moderately to severely active ulcerative colitis across four arms (200mg, 75mg, 25mg emvistegrast, or placebo). The 12-week induction phase met its primary endpoint, with the 200mg dose showing 66% clinical response versus 37% for placebo (nominal p<0.001). Clinical remission was 31% versus 8%. Results were presented as a late-breaking abstract at UEGW 2026 in Barcelona. Longer-term safety and maintenance data are still being collected. Gilead plans to initiate a Phase 3 monotherapy study in 2027.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 monotherapy study initiation (planned for 2027)
- Long-term safety and maintenance data from SWIFT extension
- Potential expansion into Crohn's disease or combination regimens
Source Filing
The SecBot filing or press-release report that triggered this drug report:
GILEAD SCIENCES, INC. 8-K GILD ·Originating report